BridgeMD
New treatment option for Chronic Coronary Disease
Official title One-Month DAPT in CABG Patients
ClinicalTrials.gov ID: NCT05997693
What this study is testing
What is Ticagrelor 90 MG?
Ticagrelor 90 MG is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for chronic coronary disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years
- Elective first-time CABG with use of ≥1 saphenous vein graft;
- Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years.
You likely can't join if
- Any indication for dual antiplatelet therapy, including
- Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI)
- Recent PCI requiring continuation of dual antiplatelet therapy after CABG
- Current or anticipated use of oral anticoagulation;
- Paroxysmal, persistent or permanent atrial fibrillation;
- Any concomitant cardiac or non-cardiac procedure;
See the full eligibility criteria
- Age ≥18 years
- Elective first-time CABG with use of ≥1 saphenous vein graft;
- Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years.
- Any indication for dual antiplatelet therapy, including
- Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI)
- Recent PCI requiring continuation of dual antiplatelet therapy after CABG
- Current or anticipated use of oral anticoagulation;
- Paroxysmal, persistent or permanent atrial fibrillation;
- Any concomitant cardiac or non-cardiac procedure;
- Planned cardiac or non-cardiac surgery within one year;
- Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy \<5 years;
- Inability to use the saphenous vein;
- Contraindications to the use of aspirin;
- Contraindications to the use of ticagrelor, including
- Known hypersensitivity to ticagrelor
- Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding)
- History of intracranial hemorrhage
- Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir)
- Inability to undergo coronary computed tomographic angiography (CCTA);
- Participating in another investigational device or drug study;
- Women of childbearing potential
- Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.
The study team makes the final eligibility decision.
Where it's taking place
- Englewood, New Jersey, United States
- Flushing, New York, United States
- New York, New York, United States
- Innsbruck, Innsbruck, Austria
- Graz, Austria
- Linz, Austria
- Vienna, Austria
- Ottawa, Ontario, Canada
- Shanghai, China, China
- Changchun, Jilian, China
- Beijing, China
- Düsseldorf, Germany
- Essen, Germany
- Freiburg im Breisgau, Germany
- Giessen, Germany
- Jena, Germany
- München, Germany
- Stuttgart, Germany
- Gothenburg, Sweden
- Malmö, Sweden
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Englewood, New Jersey, United States; Flushing, New York, United States; New York, New York, United States; Innsbruck, Innsbruck, Austria; Graz, Austria; Linz, Austria and 14 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.